IL17A and psoriasis: Anti-IL-17A BAs were most likely to induce hypertension (4.59%) and hepatic events (3.41%), and anti-IL-17A/F BAs were most likely to induce psoriasis and PSA (6.11%), followed by hypertension (4.82%) (Table 2, Supplementary Table 4, Supplementary Figure 14).